Previous 10 | Next 10 |
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announce...
AnaptysBio is a $675M clinical-stage biotechnology company focused on developing immunology therapeutics based around emerging immune control mechanisms applicable to inflammation and immuno-oncology. AnaptysBio has 7 clinical-stage therapeutics: 4 wholly-owned including the promising...
The following slide deck was published by AnaptysBio, Inc. in conjunction with this event. For further details see: AnaptysBio (ANAB) Investor Presentation - Slideshow
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announce...
AnaptysBio (ANAB): Q3 GAAP EPS of -$0.87 misses by $0.15.Cash, cash equivalents and investments of $374.5M.Press Release For further details see: AnaptysBio EPS misses by $0.15
Positive topline data from GALLOP Phase 2 clinical trial of imsidolimab in moderate to severe Generalized Pustular Psoriasis (GPP) announced in October 2020 FDA end-of-Phase 2 meeting anticipated in Q4 2020 to outline registration path of imsidolimab for the treatment of GPP, in acc...
AnaptysBio (ANAB) and GlaxoSmithKline (GSK) have amended their immuno-oncology collaboration agreement that now provides AnaptysBio with increased royalties on dostarlimab sales, a royalty on GSK’s Zejula and a one-time cash payment. Previously, dostarlimab royalties ranged from 4...
Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020 Additional 1% royalty to AnaptysBio on GSK’s global net sales of Zejula™ (niraparib) starting January 2021 GS...
Regeneron announces FDA approval for Ebola treatment REGN-EB3. Pluristem receives approval for Cohort II of Chronic Graft vs. Host Disease Study. AnaptysBio announces positive data from Phase 3 Imsidolimab trial. For further details see: Regeneron's Ebola Approval, And O...
AnaptysBio ([[ANAB]] +12.6%) had its price target lifted by Truist from $16 to $20, and keeps a Buy rating on the stockThe analyst cites the company's positive imsidolimab data from generalized pustular psoriasis study, with 6 out 8 treated patients showed improvement on CGI scale - the ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...